Financial reports
10-K
2023 FY
Annual report
1 Apr 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
31 Mar 22
Current reports
8-K
COMPANY UPDATE Revolutionizing Cardiovascular Medicine With Epigenetics and AI MARCH 2024
2 Apr 24
8-K
Unregistered Sales of Equity Securities
2 Feb 24
8-K
Entry into a Material Definitive Agreement
1 Feb 24
8-K
Termination of a Material Definitive Agreement
4 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
19 Dec 23
8-K
Other Events
6 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
25 Sep 23
8-K/A
Entry into a Material Definitive Agreement
14 Sep 23
8-K
Regulation FD Disclosure
11 Sep 23
Registration and prospectus
D
Exempt offering of security
6 Feb 24
424B5
Prospectus supplement for primary offering
1 Feb 24
S-3
Shelf registration
26 Jan 24
424B3
Prospectus supplement
15 May 23
424B3
Prospectus supplement
15 May 23
424B3
Prospectus supplement
1 May 23
POS AM
Prospectus update (post-effective amendment)
24 Apr 23
424B3
Prospectus supplement
11 Apr 23
S-1
IPO registration
5 Apr 23
424B3
Prospectus supplement
31 Mar 23
Other
EFFECT
Notice of effectiveness
2 Feb 24
UPLOAD
Letter from SEC
30 Jan 24
CORRESP
Correspondence with SEC
30 Jan 24
EFFECT
Notice of effectiveness
1 May 23
EFFECT
Notice of effectiveness
12 Apr 23
CORRESP
Correspondence with SEC
10 Apr 23
UPLOAD
Letter from SEC
10 Apr 23
EFFECT
Notice of effectiveness
25 Jan 23
CORRESP
Correspondence with SEC
20 Jan 23
UPLOAD
Letter from SEC
22 Dec 22